Vaccine hesitancy is a very challenging, and often tiring topic, for clinicians to address. Join Dr. Rachel Caskey in an engaging clinician-patient dialogue as she uses a dynamic and presumptive approach to overcome common vaccination challenges. What communication pearl will you use with your patients?

Vaccine hesitancy is a very challenging, and often tiring topic, for clinicians to address. Join Dr. Rachel Caskey in an engaging clinician-patient dialogue as she uses a dynamic and presumptive approach to overcome common vaccination challenges. What communication pearl will you use with your patients?

This Expert Exchange webcast is designed to help clinicians achieve better outcomes in patients with MDD who have an inadequate initial treatment response.

Achieving optimal outcomes when treating patients with chronic kidney disease (CKD) in type 2 diabetes (T2D) remains a challenge due to the multidisciplinary response needed to prevent progressive renal dysfunction. Low screening rates and underdiagnosis impede early interventions. On the other hand, early diagnosis and regular screening of CKD in T2D set the stage for clinicians to optimize drug therapy to prevent progression to end-stage renal disease while aggressively managing comorbid T2D and other CKD risk factors.

The results from the Protocol W and PANORAMA clinical trials have sparked a lot of talk in the retina community about what the data really mean. So how should physicians interpret these data, and what is changing for their patients with diabetic retinopathy?

Find out in this activity as Dr. Rahul Khurana and Dr. Jennifer Sun review the findings from both trials and discuss if treatment with anti-VEGF really improves outcomes for patients with moderate to severe NPDR.

Even with the recent advances in therapeutic options for patients with BRAF V600E-mutated metastatic colorectal cancer (mCRC), they still have an uphill climb ahead of them.

How will the new standard of care in the second-line setting address global challenges and unmet needs regarding molecular profiling and treatment sequencing options?

Join us as 3 experts, Dr. Scott Kopetz, Dr. Elizabeth Smyth, and Dr. Elena Elez, untangle these new advances in treatment and offer their insights on how diagnostic testing can improve patient outcomes.

With the increasing prevalence of diabetes in the United States, more individuals are at risk of losing their vision due to diabetic retinopathy every day. Fortunately, research is improving our understanding of this disease. But what does the latest information mean for our patients?

Hear Dr. Susan Bressler, Dr. Mark Dunbar, and Dr. Ruth Weinstock share their perspectives as multidisciplinary specialists treating these patients. Find out what the evidence shows and how timely referral, early diagnosis, and appropriate treatment can prevent the vision-threatening complications of diabetes.

Hear about the hottest ASCVD topics presented at the International Stroke Conference! Topics range from the latest data to risk factors to watch out for across the spectrum of disease. A stroke neurologist and 2 international experts in managing ASCVD provide hard-hitting and timely information that you can put into practice today.

There is often a delay in the diagnosis of psoriasis and/or psoriatic arthritis for people with skin of color. Among the multiple factors that cause this disparity are a low index of suspicion for such a diagnosis in skin of color and a lack of familiarity with the morphology of these conditions in richly pigmented skin. Join Drs. William Mencia and Andrew Alexis as they address pathways to overcoming these systemic and experiential healthcare barriers.

Integrating routine assessments of psoriatic arthritis (PsA)-related structural progression has proven challenging in clinical practice. Join Drs. Sergio Schwartzman, Philip Mease, and April Armstrong as they discuss evidence that frequent monitoring of PsA structural progression permits earlier intervention with effective therapies as well as provides indications for when to switch to another class of agent. They also address which therapeutic agents have been shown to impact PsA structural progression in clinical trials and provide insight into how best to incorporate collaborative treatment strategies across disciplines. These practices are likely to improve outcomes for patients with PsA, so be sure to stay informed.